ArticleBMC infectious diseases2025
Transcriptional alterations of virulence factors in Leishmania major clinical isolates harboring Leishmania RNA virus 2 (LRV2).
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Giardiavirus rewires host translation and glycolytic metabolism to support its replication inVirulence · 2026Article
- Detection of Leishmania RNA virus 2 in clinical isolates of Leishmania from Qom Province, Iran.Archives of virology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeishmaniasis is a parasitic disease caused by an intracellular protozoan, Leishmania. Various factors, including host immunity and the Leishmania species, influence the manifestation and severity of the disease. Recent investigations have shed light on the potentially significant role of Leishmania RNA virus (LRV) in the clinical prognosis of leishmaniasis. This study aims to investigate the influence of LRV2 + on various pathogenic genes of Leishmania. MATERIALS AND
methodsIn this study, 35 Leishmania isolates were obtained from patients diagnosed with cutaneous leishmaniasis (CL). Leishmania species and the presence of LRV2 + were identified with the PCR-RFLP and semi-nested PCR methods, respectively. Additionally, the RNA expression levels of cysteine protease (CP), heat shock protein 70 (HSP70), heat shock protein 83 (HSP83), glycoprotein 63 (GP63), and mannose phosphate isomerase (MPI) were assessed in LRV2 + and LRV2- Leishmania clinical isolates using RT-qPCR.
resultsOut of the 35 isolates, 20 were selected from CL patients, all confirmed as Leishmania major. These isolates were divided into two groups, LRV2 + and LRV2-, with 10 isolates in each group. RT-qPCR analysis revealed that HSP83, MPI, and GP63 gene expression levels were statistically upregulated in LRV2 + isolates compared to LRV2- isolates (P < 0.05). Although HSP70 and CP genes showed slight up-regulation in LRV2 + isolates, it was not statistically significant compared to LRV2- isolates.
conclusionThe notable increase in gene expression levels, particularly for GP63, HSP83, and MPI genes, suggests that the presence of LRV2 + may significantly influence the expression of these factors in L. major clinical isolates. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.